PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsNon-small-cell lung carcinoma
MeSH D002289 - non-small-cell lung carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D002283:Bronchogenic carcinoma
0 Companies
0 Drugs
Success rate
D002289: 
Non-small-cell lung carcinoma
86 Companies
40 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDocetaxel Docetaxel  2015-09-16   
Docetaxel Docetaxel Teva  2010-01-26   
Docetaxel Docetaxel Teva Pharma  2011-01-21   
Erlotinib Erlotinib  2015-08-28   
Gemcitabine Gemcitabine  2011-01-25   
Paclitaxel Paclitaxel  2002-01-25   
Topotecan Topotecan Teva  2009-09-21   
Vinorelbine Vinorelbine  2003-02-03   
Irinotecan Irinotecan  2008-02-27   
Novast LaboratoriesGemcitabine Gemcitabine  2019-02-14   
Topotecan Topotecan  2016-11-30   
Vinorelbine Vinorelbine  2019-08-05   
Docetaxel Docetaxel  2017-08-31   
Irinotecan Irinotecan  2017-05-26   
IngenusDocetaxel Docetaxel 2036-03-14 2022-11-22   
MylanBevacizumab Abevmy  2021-04-21   
Docetaxel Docetaxel  2023-05-11   
Docetaxel Docetaxel Mylan  2012-01-31   
Gefitinib Gefitinib Mylan  2018-09-27   
Gemcitabine Gemcitabine  2011-07-25   
Bevacizumab Lextemy     
Paclitaxel Paclitaxel  2002-01-25   
Pemetrexed Pemetrexed  2023-03-10   
Rising PharmaceuticalsTopotecan Topotecan  2012-08-28   
Vinorelbine Vinorelbine  2012-08-31   
Erlotinib Erlotinib  2014-06-11   
Johnson & JohnsonAmivantamab Rybrevant  2021-05-21   
RocheAlectinib Alecensa 2030-06-09 2015-12-11 $1,776.125 M Q4/22-Q3/23 
Bevacizumab Avastin  2005-01-12 $1,987.484 M Q4/22-Q3/23 
Pralsetinib Gavreto  2021-11-18   
Entrectinib Rozlytrek  2020-07-31 $26.653 M Y2020 
Erlotinib Tarceva  2005-09-19 $180.177 M Y2020 
Atezolizumab Tecentriq  2017-09-20 $4,406.336 M Q4/22-Q3/23 
SandozDocetaxel Docetaxel  2011-06-29   
Topotecan Hycamtin  1996-05-28   
Paclitaxel Paclitaxel  2007-12-26   
Pemetrexed Pemetrexed  2022-05-26   
Pemetrexed Pemetrexed Sandoz  2015-09-18   
Topotecan Topotecan  2011-02-25   
Irinotecan Irinotecan  2008-02-27   
Boehringer IngelheimAfatinib Gilotrif 2026-01-13 2013-07-12   
Afatinib Giotrif  2013-09-25   
Nintedanib Vargatef  2014-11-21   
AstraZenecaDurvalumab Imfinzi  2018-09-21 $2,558 M Q2/21-Q2/24 
Gefitinib Iressa  2003-05-05 $207 M Q4/20-Q2/22 
Osimertinib Tagrisso 2032-07-25 2015-11-13 $4,388 M Q2/21-Q2/24 
Tremelimumab Tremelimumab AstraZeneca  2023-02-20   
1
2
3
4
5
6
...
9
>
Clinical Trials
Historical Success Rate
Phase 1
80%
257/323
Phase 2
40%
155/389
Phase 3
40%
97/240
Approved: 57Overall Success rate: 13%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Accord Healthcare
Gemcitabine
Allergan
Docetaxel,
Paclitaxel
American Regent
Paclitaxel,
Taxoprexin
Amgen
Bevacizumab,
Sotorasib,
Benzocaine,
Transplatin,
Tbo-filgrastim,
Antithrombin iii,
Rilotumumab,
Motesanib,
Lenograstim,
Ganitumab,
Trebananib,
Serine,
AVUTOMETINIB,
CONATUMUMAB,
Dulanermin,
Retinol,
CKI-27
AstraZeneca
Durvalumab,
Osimertinib,
Gefitinib,
Tremelimumab,
Benzocaine,
Docusate,
Transplatin,
Ado-trastuzumab emtansine,
Albumin,
Antithrombin iii,
Vitamin e,
Datopotamab deruxtecan,
Monalizumab,
Oleclumab,
Domvanalimab,
Savolitinib,
Camizestrant,
Sitravatinib,
Aglatimagene besadenovec,
Cediranib,
Methionine,
Saracatinib,
Zibotentan,
Glutamic acid,
Cyproterone,
Terfenadine,
ADAVOSERTIB,
Ceralasertib,
Sodium chloride,
Sodium lactate,
DANVATIRSEN,
IMARADENANT,
Naptumomab estafenatox,
SAPITINIB,
VACTOSERTIB,
VISTUSERTIB,
Microcrystalline cellulose,
Retinol,
Ds-1062,
D-glutamate,
Cyproterone acetate,
Azd2936,
Azd9592,
Azd7789,
Azd4547,
Azd4785
Boehringer Ingelheim
Nintedanib,
Afatinib,
Nintedanib esylate,
Transplatin,
Albumin,
Antithrombin iii,
Volasertib,
Calcium dobesilate,
Nepidermin,
XENTUZUMAB,
Retinol,
Microgynon
Bristol Myers Squibb
Nivolumab,
Paclitaxel,
Ipilimumab,
Relatlimab,
Anlotinib,
Benzocaine,
Docusate,
Transplatin,
Albumin,
Antithrombin iii,
Bempegaldesleukin,
Sitravatinib,
Cilmostim,
Lucitanib,
Linrodostat,
Entinostat,
Aglatimagene besadenovec,
Guadecitabine,
Rigosertib,
Galunisertib,
Mesmulogene ancovacivec,
Brivanib alaninate,
Glutamic acid,
Regramostim,
Taurine,
SOTIGALIMAB,
Sodium chloride,
CABIRALIZUMAB,
PEGDINETANIB,
URELUMAB,
VOROLANIB,
Mrtx-849,
D-glutamate,
Adg106
Celltrion
Bevacizumab
1
2
3
4
5
6
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use